Enliven Therapeutics, Inc. $ELVN Shares Bought by HighVista Strategies LLC

HighVista Strategies LLC grew its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 83.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 259,135 shares of the company’s stock after purchasing an additional 117,619 shares during the period. Enliven Therapeutics makes up about 1.3% of HighVista Strategies LLC’s holdings, making the stock its 18th largest position. HighVista Strategies LLC owned about 0.44% of Enliven Therapeutics worth $5,304,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. BNP Paribas Financial Markets lifted its stake in shares of Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the period. Quantbot Technologies LP grew its position in Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares during the period. AlphaQuest LLC purchased a new position in Enliven Therapeutics in the third quarter valued at about $96,000. Tower Research Capital LLC TRC increased its holdings in Enliven Therapeutics by 194.3% in the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after buying an additional 3,490 shares in the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new stake in shares of Enliven Therapeutics during the 3rd quarter valued at approximately $211,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Trading Down 3.6%

Shares of NASDAQ ELVN opened at $27.77 on Monday. The company’s 50-day moving average price is $26.70 and its 200 day moving average price is $22.21. Enliven Therapeutics, Inc. has a 52 week low of $13.30 and a 52 week high of $30.98. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -14.93 and a beta of 0.33.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). As a group, research analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen cut Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.00.

Insider Buying and Selling at Enliven Therapeutics

In related news, COO Anish Patel sold 48,300 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $27.99, for a total transaction of $1,351,917.00. Following the completion of the transaction, the chief operating officer directly owned 215,011 shares in the company, valued at $6,018,157.89. The trade was a 18.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Benjamin Hohl sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $29.58, for a total value of $295,800.00. Following the completion of the sale, the chief financial officer directly owned 51,000 shares in the company, valued at approximately $1,508,580. The trade was a 16.39% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 237,180 shares of company stock valued at $6,301,233. Company insiders own 25.90% of the company’s stock.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.